Multiple Myeloma Clinical Trial

Clinical Trial Finder Multiple Myeloma Trials

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

Summary

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient

Diagnosis of Multiple Myeloma after January 1, 2017.
Karnofsky Performance Status > 70%
≥ 2 lines of prior therapy
Started new line of therapy for RRMM within the last 12 months prior to registration
Age 18-80 years of age.
English or Spanish speaking.
Willing to provide informed consent
Willing to perform study procedures.

Physician Investigator

Be a Co-Investigator
Agree to comply with study procedures

Exclusion Criteria:

Patient

Active CNS disease
Patients who have already been referred will not be included.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit